Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia
- Patients in the following disease categories will be considered eligible for this
study: *Any acute leukemia beyond an initial attempt to induce a remission or after
relapse, *Chronic Myelogenous Leukemia in Blast Phase, *Refractory Multiple Myeloma,
*Refractory non-Hodgkin's and Hodgkin's Lymphoma
- Patients must be more than 14 days beyond prior myelotoxic chemotherapy.
- Several other eligibility criteria apply.
Type of Study:
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Federal Government
- Non-Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
|Malcolm Randall VA Medical Center
||Gainesville, Florida 32608